2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction,
PET
[18F]FMISO
azomycin nucleosides
small animal imaging
tumor hypoxia
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
15 Feb 2019
15 Feb 2019
Historique:
received:
03
12
2018
revised:
04
02
2019
accepted:
12
02
2019
entrez:
21
2
2019
pubmed:
20
2
2019
medline:
20
2
2019
Statut:
epublish
Résumé
The benefits of PET imaging of tumor hypoxia in patient management has been demonstrated in many examples and with various tracers over the last years. Although, the optimal hypoxia imaging agent has yet to be found, 2-nitroimidazole (azomycin) sugar derivatives-mimicking nucleosides-have proven their potential with [
Identifiants
pubmed: 30781409
pii: ph12010031
doi: 10.3390/ph12010031
pmc: PMC6469291
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Biochem Cell Biol. 2002;80(5):639-44
pubmed: 12440703
Chem Pharm Bull (Tokyo). 2003 Apr;51(4):399-403
pubmed: 12672991
Oncogene. 2003 Oct 20;22(47):7524-36
pubmed: 14576856
Mol Pharmacol. 2003 Dec;64(6):1512-20
pubmed: 14645682
Nucleosides Nucleotides Nucleic Acids. 2004;23(1-2):361-73
pubmed: 15043160
J Nucl Med. 2005 Jan;46(1):106-13
pubmed: 15632040
Cancer Metastasis Rev. 2007 Mar;26(1):85-110
pubmed: 17345146
Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1566-75
pubmed: 17447061
Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2294-303
pubmed: 18682937
Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):450-63
pubmed: 20183595
J Nucl Med. 2010 Sep;51(9):1386-94
pubmed: 20720045
Acta Oncol. 2010 Oct;49(7):922-33
pubmed: 20831479
Radiother Oncol. 2011 Dec;101(3):369-75
pubmed: 21872957
Radiat Oncol. 2011 Nov 25;6:165
pubmed: 22118419
J Invest Dermatol. 2013 Oct;133(10):2436-2443
pubmed: 23474946
Mol Aspects Med. 2013 Apr-Jun;34(2-3):529-47
pubmed: 23506887
Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1523-31
pubmed: 23740374
Am J Nucl Med Mol Imaging. 2014 Sep 06;4(6):490-506
pubmed: 25250200
J Nucl Med. 2014 Nov;55(11):1772-7
pubmed: 25324522
Clin Cancer Res. 2015 Jan 15;21(2):249-57
pubmed: 25421725
PLoS One. 2015 Apr 22;10(4):e0124665
pubmed: 25902054
Cancer Res. 2015 Sep 15;75(18):3912-24
pubmed: 26294212
Recent Results Cancer Res. 2016;198:123-42
pubmed: 27318684
Nat Rev Clin Oncol. 2016 Dec;13(12):725-739
pubmed: 27430748
Bioorg Med Chem. 2016 Nov 1;24(21):5326-5339
pubmed: 27614920
Nucl Med Biol. 2016 Dec;43(12):759-769
pubmed: 27693670
Front Oncol. 2017 Jan 25;7:10
pubmed: 28180110
Curr Radiopharm. 2017;10(2):93-101
pubmed: 28294075
Acta Oncol. 2017 Nov;56(11):1571-1576
pubmed: 28891398
Oncotarget. 2017 Oct 7;8(55):94969-94979
pubmed: 29212283
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2201-2217
pubmed: 30128659
J Nucl Med. 1997 Jul;38(7):1155-60
pubmed: 9225812